Progression of coronary artery calcification in predialysis patients

被引:78
作者
Russo, Domenico
Corrao, Salvatore
Miranda, Ida
Ruocco, Carolina
Manzi, Simona
Elefante, Rosanna
Brancaccio, Diego
Cozzolino, Mario
Biondi, Maria L.
Andreucci, Vittorio E.
机构
[1] Univ Naples Federico II, Sch Med, Dept Nephrol, Naples, Italy
[2] Univ Palermo, Lab Clin Epidemiol Biostat & Knowledge Management, Palermo, Italy
[3] Univ Milan, Div Renal, Milan, Italy
[4] Univ Milan, S Paolo Hosp, Milan, Italy
关键词
coronary artery calcification; predialysis patients; phosphorus; progression of calcification;
D O I
10.1159/000100044
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: In patients on dialysis coronary artery calcification (CAC) rapidly proceeds due to impaired mineral metabolism and/or exogenous calcium load. Progression has not been assessed in patients with chronic kidney disease not yet requiring dialysis (CKD patients). In this study, rate and determinants of CAC progression have been evaluated in CKD patients who are exposed to minor derangement of mineral metabolism and calcium load. Methods: Consecutive patients were enrolled. Exclusion criteria were: symptomatic coronary disease, arrhythmia, myocardial infarction, and diabetes. Serum calcium, phosphorus, parathyroid hormone, homocysteine, C-reactive protein, triglycerides, total cholesterol, high-and low-density lipoprotein cholesterol were serially measured. Fetuin-A was assessed at entry into the study. CAC progression was detected by measuring total calcium score (TCS) with computed tomography. Initial and final scans were obtained. Predictive factors of progression were investigated. Results: Fifty-three patients had CKD (stage 3 - 5 CKD; K-DOQI classification) not yet requiring dialysis, and 60 patients had normal renal function (NRF patients). Follow-up lasted 24 +/- 4.2 months (mean +/- SE). Patients with CAC were older with lower serum fetuin-A. TCS increased from 73 +/- 17 to 80 +/- 20 (mean +/- SE; p = NS) in NRF patients, and from 384 8 116 to 602 8 140 ( mean 8 SE; p < 0.01) in CKD patients. Serum phosphorus [OR = 1.97 (1.14 - 3.41, 95% CI); p = 0.015] was the only variable that was associated with CAC progression. Cardiovascular events occurred in CKD patients with CAC. Conclusion: CAC progression was prominent in CKD patients and correlated with serum phosphorus. Fatal and nonfatal cardiovascular events were more frequent in CKD patients. Studies are required to ascertain whether the attainment of serum phosphorus concentration lower than that suggested by current guidelines may reduce CAC progression and ultimately mortality. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:152 / 158
页数:7
相关论文
共 28 条
[1]   Influence of lipid-lowering therapy on the progression of coronary artery calcification - A prospective evaluation [J].
Achenbach, S ;
Ropers, D ;
Pohle, K ;
Leber, A ;
Thilo, C ;
Knez, A ;
Menendez, T ;
Maeffert, R ;
Kusus, M ;
Regenfus, M ;
Bickel, A ;
Haberl, R ;
Steinbeck, G ;
Moshage, W ;
Daniel, WG .
CIRCULATION, 2002, 106 (09) :1077-1082
[2]  
[Anonymous], 1993, NUTR KIDNEY
[3]   Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
London, GM .
HYPERTENSION, 2001, 38 (04) :938-942
[4]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[5]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[6]   Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis [J].
Block, GA ;
Spiegel, DM ;
Ehrlich, J ;
Mehta, R ;
Lindbergh, J ;
Dreisbach, A ;
Raggi, P .
KIDNEY INTERNATIONAL, 2005, 68 (04) :1815-1824
[7]   Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].
Braun, J ;
Oldendorf, M ;
Moshage, W ;
Heidler, R ;
Zeitler, E ;
Luft, FC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401
[8]   Effect of HMG-Coa reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography [J].
Callister, TQ ;
Raggi, P ;
Cooil, B ;
Lippolis, NJ ;
Russo, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (27) :1972-1978
[9]   Determinants of progressive vascular calcification in haemodialysis patients [J].
Chertow, GM ;
Raggi, P ;
Chasan-Taber, S ;
Bommer, J ;
Holzer, H ;
Burke, SK .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (06) :1489-1496
[10]   Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Raggi, P .
KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252